These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 27174237)

  • 1. Incidence and types of adverse events during mass vaccination campaign with the meningococcal a conjugate vaccine (MENAFRIVAC™) in Cameroon.
    Ateudjieu J; Stoll B; Nguefack-Tsague G; Yakum MN; Mengouo MN; Genton B
    Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1170-1178. PubMed ID: 27174237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010.
    Ouandaogo CR; Yaméogo TM; Diomandé FV; Sawadogo C; Ouédraogo B; Ouédraogo-Traoré R; Pezzoli L; Djingarey MH; Mbakuliyemo N; Zuber PL
    Vaccine; 2012 May; 30 Suppl 2():B46-51. PubMed ID: 22230584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccines safety; effect of supervision or SMS on reporting rates of adverse events following immunization (AEFI) with meningitis vaccine (MenAfriVac™): a randomized controlled trial.
    Ateudjieu J; Stoll B; Nguefack-Tsague G; Tchangou C; Genton B
    Vaccine; 2014 Sep; 32(43):5662-8. PubMed ID: 25160064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety profile of the meningococcal conjugate vaccine (Menafrivac™) in clinical trials and vaccination campaigns: a review of published studies.
    Ateudjieu J; Stoll B; Bisseck AC; Tembei AM; Genton B
    Hum Vaccin Immunother; 2020 Jun; 16(6):1245-1259. PubMed ID: 31403358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring adverse events following immunization with a new conjugate vaccine against group A meningococcus in Niger, September 2010.
    Chaibou MS; Bako H; Salisou L; Yaméogo TM; Sambo M; Kim SH; Djingarey MH; Zuber PL; Perea WA; Pezzoli L
    Vaccine; 2012 Jul; 30(35):5229-34. PubMed ID: 22709955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From Agadez to Zinder: estimating coverage of the MenAfriVac™ conjugate vaccine against meningococcal serogroup A in Niger, September 2010 - January 2012.
    Caini S; Beck NS; Yacouba H; Maiga I; Chaibou I; Hinsa I; Adakal A; Issoufou A; Kim SH; Pezzoli L
    Vaccine; 2013 Mar; 31(12):1597-603. PubMed ID: 23337027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A field based evaluation of adverse events following MenAfriVac® vaccine delivered in a controlled temperature chain (CTC) approach in Benin.
    Steffen C; Tokplonou E; Jaillard P; Dia R; Alladji MN; Gessner B
    Pan Afr Med J; 2014; 18():344. PubMed ID: 25574320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving community based AEFI (Adverse Events Following Immunization) reporting rate through telephone "beep" in a Cameroon health district: a randomized field trial.
    Tsafack M; Ateudjieu J
    Pan Afr Med J; 2015; 22():351. PubMed ID: 26985269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso--implications for introduction of PsA-TT into the Expanded Programme on Immunization.
    Meyer SA; Kambou JL; Cohn A; Goodson JL; Flannery B; Medah I; Messonnier N; Novak R; Diomande F; Djingarey MH; Clark TA; Yameogo I; Fall A; Wannemuehler K
    Vaccine; 2015 Mar; 33(12):1492-8. PubMed ID: 25636915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance of adverse effects during a vaccination campaign against meningitis C.
    Laribière A; Miremont-Salamé G; Reyre H; Abouelfath A; Liège L; Moore N; Haramburu F
    Eur J Clin Pharmacol; 2005 Dec; 61(12):907-11. PubMed ID: 16328316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada.
    De Serres G; Billard MN; Gariépy MC; Rouleau I; Toth E; Landry M; Boulianne N; Gagné H; Gilca V; Deceuninck G; Ouakki M; Skowronski DM
    Vaccine; 2018 Dec; 36(52):8039-8046. PubMed ID: 30467063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postmarketing surveillance of adverse events following meningococcal B vaccination: data from Apulia Region, 2014-19.
    Stefanizzi P; Bianchi FP; Spinelli G; Amoruso F; Ancona D; Stella P; Tafuri S
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-6. PubMed ID: 34435938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surveillance of adverse events following immunisation: Australia 2002 to 2003.
    Lawrence G; Boyd I; McIntyre P; Isaacs D
    Commun Dis Intell Q Rep; 2004; 28(3):324-38. PubMed ID: 15574056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.
    Breugelmans JG; Lewis RF; Agbenu E; Veit O; Jackson D; Domingo C; Böthe M; Perea W; Niedrig M; Gessner BD; Yactayo S;
    Vaccine; 2013 Apr; 31(14):1819-29. PubMed ID: 23395587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Impact of Controlled Temperature Chain (CTC) approach on immunization coverage achieved during the preventive vaccination campaign against meningitis A using MenAfriVac in Togo in 2014].
    Landoh DE; Kahn AL; Lacle A; Adjeoda K; Saka B; Yaya I; Nassoury DI; Kalao A; Makawa MS; Biey NJ; Bita A; Toke YT; Dörte P; Imboua L; Ronveaux O
    Pan Afr Med J; 2017; 27():38. PubMed ID: 28761614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Microeconomic evaluation of a mass preventive immunisation campaign against meningococcal meningitis and yellow fever in Senegal in 1997].
    da Silva A; Parent du Châtelet I; Beckr Gaye A; Dompnier JP; Seck I
    Sante; 2003; 13(4):215-23. PubMed ID: 15047438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active Surveillance for Adverse Events After a Mass Vaccination Campaign With a Group A Meningococcal Conjugate Vaccine (PsA-TT) in Mali.
    Vannice KS; Keita M; Sow SO; Durbin AP; Omer SB; Moulton LH; Yaméogo TM; Zuber PL; Onwuchekwa U; Sacko M; Diomandé FV; Halsey NA
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S493-500. PubMed ID: 26553680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events following immunisation with four-component meningococcal serogroup B vaccine (4CMenB): interaction with co-administration of routine infant vaccines and risk of recurrence in European randomised controlled trials.
    Zafack JG; Bureau A; Skowronski DM; De Serres G
    BMJ Open; 2019 May; 9(5):e026953. PubMed ID: 31110098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign-Burkina Faso, 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(50):1022-4. PubMed ID: 23254256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring of adverse events during the 2003 mass vaccination campaign with a trivalent meningococcal A/C/W135 polysaccharide vaccine in Burkina Faso.
    Bentsi-Enchill AD; Zongo I; Khamassi S; Pless R; Thombiano R; Tiéndrebéogo S; Nelson CB; Duclos P
    Vaccine; 2007 Sep; 25 Suppl 1():A72-8. PubMed ID: 17544552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.